Methods of diagnosis and treatment of osteoporosis

Abstract

A method of detecting osteoporosis in a mammalian is disclosed herein which includes: a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone molecule, or a bacteria produced. Also provided herein is a method of treating or preventing osteoporosis caused by a bone disease which includes administering to a mammalian subject a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation. The osteoporosis can be caused by a bone disease induced by bone infectious agents such as viruses, bacteria, fungi, protozoa and parasites.

1 . A method of detecting osteoporosis in a mammalian comprising:
 a) obtaining a sample of a bone related tissue or cells; and   b) measuring the concentration of at least one marker selected from the group consisting of infectious agents, infectious agent produced factors, and heat shock proteins (HSPs).   
   
   
       2 . The method of  claim 1  further comprising comparing the concentration of a first assay with concentrations of a second or more assays from the same individual over a period of time or against a standard concentration. 
   
   
       3 . The method of  claim 1  wherein the bone related tissue or cells are obtained under conditions that do not induce a HSP response in the mammalian subject. 
   
   
       4 . The method of  claim 3  wherein the HSP is selected from the group consisting of HSP 70, HSP 60, HSP 90, gp 96, cpn1O, cpn2O, ubiquitin, and cpn 30. 
   
   
       5 . The method of  claim 2  wherein the time period between the first assay and the second assay is at least about 12 hours. 
   
   
       6 . The method of  claim 1  wherein the sample comprises bone cells or body fluid. 
   
   
       7 . (canceled) 
   
   
       8 . The method of  claim 3  wherein the HSP is HSP 70. 
   
   
       9 - 11 . (canceled) 
   
   
       12 . The method of  claim 1  wherein the pathogen is selected from the group consisting of bacteria, viruses, protozoa, parasites and fungi. 
   
   
       13 . The method of  claim 1  wherein the pathogen is selected from the group consisting of bacterial produced factors, viral produced factors, protozoal produced factors, parasitic produced factors and fungal produced factors. 
   
   
       14 . The method of  claim 12  wherein the bacteria is  Escherichia coli.    
   
   
       15 - 19 . (canceled) 
   
   
       20 . A method of treating or preventing osteoporosis caused by an infectious agent, an infectious agent produced factor, or a bone disease comprising administering to a mammalian subject a therapeutically effective amount of a formulation selected from the group consisting of an HSP antigenic formulation and an infectious agent antigenic formulation. 
   
   
       21 . The method of  claim 20  wherein the bone disease is induced by bone infectious agents selected from the group consisting of viruses, bacteria, fungi, protozoa and parasites. 
   
   
       22 . The method of  claim 20  wherein the HSP is complexed with an antigenic material or formulated in combination with an adjuvant. 
   
   
       23 . The method of  claim 20  wherein the antigenic material is a peptide or a protein having an antigenic determinant of a virus, bacteria, fungi, protozoa or parasite that induces a bone disease. 
   
   
       24 . The method of  claim 21  wherein the antigenic material includes an antigenic determinant of a virus selected from the group consisting of immunodeficiency virus type I (HIV-1), human immunodeficiency virus type II (HIV-II), hepatitis type A, hepatitis type B, hepatitis type C, influenza, Varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus and polio virus. 
   
   
       25 . The method of  claim 20  wherein the HSP is selected from the group consisting of HSP 60, HSP 70, HSP 90, gp 96, cpn 10, cpn 20, ubiquitin, cpn 30, and combinations thereof. 
   
   
       26 . The method of  claim 20  wherein the osteoporosis is osteopenia. 
   
   
       27 . The method of  claim 20  wherein the osteoporosis is caused by a bacteria or a bacteria produced factor. 
   
   
       28 . A kit for use in the method of  claim 1 . 
   
   
       29 . A pharmaceutically acceptable composition for administration to a patient for use in the method of  claim 20 .